At its annual shareholders’ meeting, Grifols announced a €1,400 million capital investment plan through 2022. 66% will be allotted to the Bioscience Division, 10% to the Diagnostic Division and 3% to the Hospital Division. The company's manufacturing facilities in Spain will receive more than €300 million.
The biotech group has invested more than €1,370 million in R&D projects over the last five years, including the AMBAR clinical trial against Alzheimer's.
Grifols' co-CEO Raimon Grífols Roura underscored the vital role of its global talent pool: "In 2018, we expanded our workforce by 16% to 21,230 employees, of which 59% are women.
Recently, Grifols reaches a strategic alliance with Shanghai RAAS to promote the sale of hemoderivatives and transfusion diagnostic solutions in China.
Photo: General meeting of shareholders held at the end of May - © Grifols
Comments